Vericel Corporation · NASDAQ:VCEL
Vericel — Q2 2025 Earnings Presentation
7 slides from Vericel's earnings presentation, Jul 31, 2025
Slide 1: Vericel Q2 2025 Results
VERICEL Q2 2025 RESULTS JULY 31, 2025
Slide 2: Safe Harbor
Safe Harbor Vericel cautions you that all statements other than statements of our manufacturing operations to meet the demand for our cell adverse developments affecting financial institutions, companies in historical fact included in this presentation that address activities, therapy products, incl
Slide 3: Q2 2025 Financial Highlights and Key Business Updates
Q2 2025 Financial Highlights Key Business Updates Total revenue of $63.2M Record second quarter total revenue and MACI revenue MACI revenue growth of 21% to $53.5M Second highest number of MACI biopsies in a quarter since launch, with second highest biopsies in any month in April Burn Care revenue o
Slide 4: MACI Arthro Launch Progress
MACI Arthro Launch Progress ~600 Trained Surgeons Since Launch, With Highest Year-to-Date Biopsy and Implant Growth Significantly Training Activity to Date in Q2 Higher for MACI Arthro Trained Surgeons ✓ Biopsy growth rate accelerated for surgeons trained on MACI Arthro in Q2 ~600 ✓ MACI implants to
Slide 5: Q2 2025 Revenue Details
Q2 2025 Revenue Details Total Revenue ($M) $80 $70 $63.2 $1.2 NexoBrid $60 $52.7 $8.6 $45.9 $0.8 Epicel $50 $7.8 MACI growth of 21% vs. $37.0 $40 $0.2 * $9.6 prior year MACI $8.2 $30 $53.5 $20 $44.1 $36.3 $28.6 $10 $0 Q2 2022 Q2 2023 Q2 2024 Q2 2025 *NexoBrid revenue related to the U.S. Biomedical A
Slide 6: Q2 2025 Financial Results
Q2 2025 Financial Results Three Months Ended Six Months Ended June 30, June 30, Unaudited, amounts in millions except per share amounts 2025 2024 2025 2024 Net Revenue $63.2 $52.7 $115.8 $103.9 Gross Profit 46.6 36.6 82.9 72.0 Gross Margin 74% 70% 72% 69% Research and Development 6.7 7.4 14.0 13.8 S
Slide 7: Reconciliation of Reported Net Income (Loss) to Adjusted EBITDA (Non-GAAP Measure)
Reconciliation of Reported Net Income (Loss) to Adjusted EBITDA (Non- GAAP Measure) – Unaudited Three Months Ended Six Months Ended (unaudited, amounts in thousands) June 30, June 30, Adjusted EBITDA (In Thousands) 2025 2024 2025 2024 Net Loss (GAAP) $ (553) $ (4,682) $ (11,799) $ (8,544) Stock-base